Next Article in Journal
Phytochemicals and Other Characteristics of Croatian Monovarietal Extra Virgin Olive Oils from Oblica, Lastovka and Levantinka Varieties
Previous Article in Journal
Self-Assembled Polyelectrolyte Nanoparticles as Fluorophore-Free Contrast Agents for Multicolor Optical Imaging
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Antifungal Activity of the Derivatives of Novel Pyrazole Carboxamide and Isoxazolol Pyrazole Carboxylate

College of Chemistry and Pharmaceutical Sciences, Qingdao Agricultural University, Qingdao 266109, China
*
Author to whom correspondence should be addressed.
Molecules 2015, 20(3), 4383-4394; https://doi.org/10.3390/molecules20034383
Submission received: 13 January 2015 / Revised: 17 February 2015 / Accepted: 4 March 2015 / Published: 9 March 2015
(This article belongs to the Section Organic Chemistry)

Abstract

:
A series of pyrazole carboxamide and isoxazolol pyrazole carboxylate derivatives were designed and synthesized in this study. The structures of the compounds were elucidated based on spectral data (infrared, proton nuclear magnetic resonance and mass spectroscopy). Then, all of the compounds were bioassayed in vitro against four types of phytopathogenic fungi (Alternaria porri, Marssonina coronaria, Cercospora petroselini and Rhizoctonia solani) using the mycelium growth inhibition method. The results showed that some of the synthesized pyrazole carboxamides displayed notable antifungal activity. The isoxazole pyrazole carboxylate 7ai exhibited significant antifungal activity against R. solani, with an EC50 value of 0.37 μg/mL. Nonetheless, this value was lower than that of the commercial fungicide, carbendazol.

1. Introduction

Phytopathogenic fungi, such as Rhizoctonia solani Kuhn, Alternaria porri (Ell) Ciferri, Marssonina coronaria (Ell.et Davis) Davis and Cercospora petroselini Saccardo, pose serious threats to agriculture. They are broad host-range pathogens and infect many crops worldwide, including rice, onions, apples and cucumbers. Many pesticides have been developed and applied to control these diseases with the progression of the modern agrochemical industry. However, the increased microbial resistance of pathogens to known antibiotics facilitates the urgent need for new fungicides [1].
As with many other five-membered heterocyclic compounds, pyrazoles and their derivatives attract increasing attention in the fields of pharmacology and medicine because of their various bioactivities, including antifungal [2], anti-inflammatory [3], antiviral [4], antioxidant [5], cytotoxic [6], antihypertensive [7], A3 adenosine receptor antagonistic [8], antibacterial [9], tranquilizing, psychoanaleptic, muscle-relaxant, hypnotic, antidepressant, ulcerogenic and analgesic activities [10]. They are also highly significant in agrichemistry, and many of these compounds have been widely used, given their fungicidal [11], insecticidal [12] and herbicidal activities [13].
Pyrazole carboxamide derivatives are important heterocyclic compounds in the development of medicines and pesticides because of their broad spectrum of biological activities, including insecticidal [14], fungicidal [15], herbicidal [13] and acaricidal activity [16]. Many recent studies have been conducted on the synthesis and biological activity of these derivatives. Pyrazole carboxamide derivatives, such as penthiopyrad, furametpyr, penflufen, isopyrazam and bixafen, which could inhibit the succinate dehydrogenase, have been developed and commercialized as fungicides in succession [17]. In addition, many isoxazole compounds, including oxacillin and sulfamethoxazole, have been developed as pesticides and drugs, because of their insecticidal, herbicidal, antiviral and antifungal activities. Isoxazole derivatives have received much attention, because of their wide application in medicine and pesticide chemistry [18].
In view of the facts and to explore the potential antifungal activity of pyrazole derivatives, a series of pyrazole carboxamide and isoxazolol pyrazole carboxylate derivatives are designed and synthesized in the current study. Pyrazole carbonyl chloride is synthesized from pyrazole carboxylic acid and thionyl chloride. Then, 18 novel pyrazole carboxamides and two isoxazolol pyrazole carboxylates are synthesized by reacting pyrazole carbonyl chloride with amines and with isoxazol-3-ol, respectively. The structures of all of the synthesized compounds are unequivocally determined through a comprehensive analysis of spectroscopic data from infrared (IR), mass spectroscopy (MS) and proton nuclear magnetic resonance (1H-NMR).

2. Results and Discussion

2.1. Chemistry

The synthesis of the derivatives of pyrazole carboxamide and isoxazolol pyrazole carboxylate is outlined in Scheme 1. Acetoacetic ester (1ab) and triethyl orthoformate were dissolved in acetic anhydride, refluxed and then converted into 2-ethoxymethylene acetoacetic ester derivatives (2ab) [19]. Ethyl 1H-pyrazole-4-carboxylate (3ab) was prepared by reacting Compounds 2ab with hydrazine hydrate [20]. Intermediate 1H-pyrazole-4-carboxylic acids (5ab) were obtained as light-yellow crystals from Compounds 3ab by successively performing a substitution reaction using dimethyl sulfate, saponification with NaOH and acidification using HCl [21]. Subsequently, Compounds 5ab were refluxed in SOCl2 to yield pyrazole acid chlorides (6ab) [22]. Finally, the target compounds of pyrazole carboxamides and isoxazolol pyrazole carboxylates (7aabk) were obtained by reacting 6ab with different substituted amines [23] and with isoxazol-3-ol, respectively. IR, MS and 1H-NMR data were applied to confirm the structures of the new synthesized compounds. The synthesized compounds above were published in our Chinese Patents CN103554026A and CN103524417A [24,25].
Scheme 1. Synthesis route of the pyrazole derivatives.
Scheme 1. Synthesis route of the pyrazole derivatives.
Molecules 20 04383 g001

2.2. Antifungal Activity

The initial concentration was set at 100 μg/mL for antifungal activity screening in vitro. If the percentage inhibition exceeded 50%, a series of concentrations of the compounds was tested to evaluate their EC50 values. Carbendazol was selected as the positive control.
As suggested in Table 1, most of the synthesized pyrazole derivatives exhibited antifungal activity to some extent. Though the EC50 value of these compounds was higher than that of the positive control, carbendazol, a few pyrazole carboxamides (7af, 7bc, 7bg, 7bh and 7bi) displayed remarkable antifungal activity. According to the literature [17] reported, a bigger group introduced into the ortho position of the aniline part of this type of compound would strengthen the antifungal activity. The simple anilines applied in this study only gave moderate antifungal activity, so the bioactivity and the structures of the pyrazole derivatives should be researched further.
Table 1. EC50 values of the pyrazole derivatives against four plant pathogenic fungi in vitro.
Table 1. EC50 values of the pyrazole derivatives against four plant pathogenic fungi in vitro.
CompoundR1R2EC50 (μg/mL)
A. porriM. coronariaC. petroseliniR. solani
7aa Molecules 20 04383 i022 Molecules 20 04383 i001------31.39
7ab Molecules 20 04383 i022 Molecules 20 04383 i00280.76--38.41--
7ac Molecules 20 04383 i022 Molecules 20 04383 i00352.5684.74--40.00
7ad Molecules 20 04383 i022 Molecules 20 04383 i004----6.3218.15
7ae Molecules 20 04383 i022 Molecules 20 04383 i00565.12----14.89
7af Molecules 20 04383 i022 Molecules 20 04383 i00663.047.8735.905.23
7ag Molecules 20 04383 i022 Molecules 20 04383 i00754.8676.1251.0016.91
7ah Molecules 20 04383 i022 Molecules 20 04383 i008------69.45
7ai Molecules 20 04383 i022 Molecules 20 04383 i0092.243.2110.190.37
7ba Molecules 20 04383 i023 Molecules 20 04383 i010--35.9422.4716.81
7bb Molecules 20 04383 i023 Molecules 20 04383 i011--74.5427.8219.47
7bc Molecules 20 04383 i023 Molecules 20 04383 i01210.1014.925.433.40
7bd Molecules 20 04383 i023 Molecules 20 04383 i013----74.3827.37
7be Molecules 20 04383 i023 Molecules 20 04383 i01423.1213.0013.448.55
7bf Molecules 20 04383 i023 Molecules 20 04383 i01572.2061.29--81.72
7bg Molecules 20 04383 i023 Molecules 20 04383 i01611.227.9327.434.99
7bh Molecules 20 04383 i023 Molecules 20 04383 i01724.7625.486.995.93
7bi Molecules 20 04383 i023 Molecules 20 04383 i01821.019.0832.407.69
7bj Molecules 20 04383 i023 Molecules 20 04383 i01911.4615.86--8.32
7bk Molecules 20 04383 i023 Molecules 20 04383 i02035.05----28.88
carbendazol0.990.960.961.00
“--” The percentage of inhibition is lower than 50% at 100 μg/mL.
It was interesting that the isoxazolol pyrazole carboxylate 7ai showed significant antifungal activity against A. porri, M. coronaria, C. petroselini and R. solani, with EC50 values of 2.24, 3.21, 10.29 and 0.37 μg/mL, respectively. The EC50 value of this compound against R. solani was lower than that of the positive control, carbendazol (EC50, 1.00 μg/mL).
The EC50 values of the isoxazolol pyrazole carboxylate 7bk were 35.05, over 100, over 100 and 28.88 μg/mL against A. porri, M. coronaria, C. petroselini and R. solani, respectively (Table 1). The results of the preliminary structure-activity relationship (SAR) analysis suggested that the antifungal activity of the synthesized isoxazolol pyrazole carboxylate was significantly weakened when the methyl group at the C-3 of the pyrazole ring (7ai) was substituted with a trifluoromethyl group (7bk).

3. Experimental Section

3.1. Chemistry

All of the reagents and solvents were either chemically pure or purified in accordance with standard methods. Reactions were monitored through thin-layer chromatography (TLC) using precoated silica gel plates (silica gel GF 254, Qingdao Marine Chemistry Co. Ltd., Qingdao, China), and the spots were visualized with UV (254 nm). All of the melting points were detected with a WRS-1A type melting point apparatus (ShangHai Suoguang Electric Tech Co., Ltd., Shanghai, China), and the thermometer was not corrected. IR spectra were recorded on a Nicolet IR-200 (Thermo Electron, Madison, WI, USA) spectrophotometer. 1H-NMR spectra were captured with Bruker AV-500 and AV-400 spectrometers, and tetramethylsilane was applied as an internal standard. High-resolution electrospray ionization mass spectroscopy (HR-ESI-MS) spectra were observed with a Micromass Q-TOF spectrometer (Waters Corp., Manchester, UK).

3.2. General Procedure for the Preparation of 2ab

A mixture of acetoacetic ester (0.60 mol) (1ab), triethyl orthoformate (0.72 mol) and acetic anhydride (1.08 mol) was stirred and heated under reflux until the 1ab was no longer monitored by TLC. Then, the reaction mixture was evaporated in vacuo. The distillates of T = 140 °C–160 °C (3 KPa) were collected to produce 2-ethoxymethylene acetoacetic esters (2ab) as a light-yellow liquid with yields ranging from 70% to 90%.

3.3. General Procedure for the Preparation of 3ab

The acetoacetic ester of 2-ethoxymethylene (0.2 mol) (2ab) was dissolved in ethanol (150 mL) in an ice-water bath, and 80% hydrazine hydrate (0.4 mol) was added dropwise. The mixture reacted at room temperature until the 2ab was fully consumed, as detected by TLC. Subsequently, the reaction mixture was concentrated in vacuo. The residue was extracted with 1,2-dichloroethane, washed with water and brine, dried over anhydrous sodium sulfate and then concentrated in vacuo to obtain ethyl 1H-pyrazole-4-carboxylate (3ab) as either light-yellow liquids or solids.

3.4. General Procedure for the Preparation of 5ab

Ethyl 1H-pyrazole-4-carboxylate (3ab, 0.5 mol) and NaHCO3 (0.6 mol) were dissolved in toluene (120 mL). (CH3)2SO4 (0.24 mol) was dropped gradually into the solution while the temperature was maintained at 20 °C–30 °C via an ice-water bath. Then, the solution reacted at a temperature of 50 °C with a water bath and was monitored by TLC. Once the reaction was complete, the reaction solution was filtered. A light-yellow solution was then obtained and washed with ice water. The upper toluene solution was concentrated in vacuo to produce ethyl 1-methyl-1H-pyrazole-4-carboxylate (4ab). Subsequently, sodium hydroxide solution (0.12 mol NaOH dissolved in 45 mL water) was added to a solution of Compounds 4ab (0.1 mol) in EtOH (95%, 50 mL) and then reacted at room temperature for approximately 2 h. The solution was concentrated in vacuo to remove most of the ethanol. The pH level was then adjusted to 3–4 with HCl. The reaction mixture was filtered, and the filtrate was recrystallized with ethyl acetate to produce pyrazole acids (5ab) as light-yellow crystalline solids.

3.5. General Procedure for the Preparation of 7aabk

Pyrazole acid chlorides 6ab were prepared by refluxing 4ab in thionyl chloride for 8 h. Pyrazole acid chlorides 6ab (12 mmol) in anhydrous tetrahydrofuran (THF; 30 mL) were slowly added to a solution of amine derivatives or 5-methylisoxazol-3-ol (10 mmol) and K2CO3 (1.38 g, 10 mmol) in anhydrous THF (30 mL) at a controlled temperature of 5 °C. The reaction proceeded at room temperature until 6ab was no longer tested by TLC. The reaction solution was then filtered and the solvent distilled. The residue was dissolved in ethyl acetate, washed with water and brine, dried over anhydrous sodium sulfate and recrystallized to generate the target pyrazole carboxamides and isoxazolol pyrazole carboxylates (7aabk). The product yields ranged from 40% to 80%. All 20 compounds were novel, and the physical and spectral data for these compounds are listed below.
1,3-Dimethyl-N-(2-hydroxyl)benzyl-1H-pyrazole-4-carboxamide (7aa): Bright brown crystal, yield of 77.9%, m.p. 193.0–193.1 °C. 1H-NMR (CDCl3, 500 MHz) δ: 8.82 (s, 1H, NH), 7.86 (s, 1H, pyrazole H), 7.61 (s, 1H, -OH), 7.14–7.16 (m, 1H, Ar-H), 7.13–7.09 (m, 1H, Ar-H), 7.08–7.05 (m, 1H, Ar-H), 6.89 (t, J = 1.5 Hz, 1H, Ar-H), 3.89 (s, 3H, N-CH3), 2.56 (s, 3H, pyrazole CH3); IR (KBr): ν 3431, 1643, 1593, 1544, 1452, 1382, 1278 cm−1; HR-ESI-MS m/z: 232.1084 [M+H]+ (calcd. for C12H14N3O2, 232.1081).
1,3-Dimethyl-N-(4-hydroxyl)benzyl-1H-pyrazole-4-carboxamide (7ab): Gray needle crystal, yield of 80.5%, m.p. 208.0–208.7 °C. 1H-NMR (CDCl3, 500 MHz) δ: 7.76 (s, 1H, pyrazole H), 7.43 (m, 2H, Ar-H), 6.84 (d, J = 8.5 Hz, 2H, Ar-H), 4.78 (s, 1H, -OH), 3.89 (s, 3H, N-CH3), 2.54 (s, 3H, pyrazole CH3); IR (KBr): ν 3510, 3290, 1639, 1539, 1515, 1448, 1245, 1166 cm−1; HR-ESI-MS m/z: 232.1081 [M+H]+ (calcd. for C12H14N3O2, 232.1081).
1,3-Dimethyl-N-2',4'-dichlorobenzyl-1H-pyrazole-4-carboxamide (7ac): White lamellar crystal, yield of 77.9%, m.p. 169.1–169.3 °C. 1H-NMR (CDCl3, 500 MHz) δ: 8.52 (d, J = 9.0 Hz, 1H, Ar-H), 7.86 (s, 1H, pyrazole H), 7.42 (d, J = 2.5 Hz, 1H, Ar-H), 7.27–7.30 (m, 1H, Ar-H), 3.91 (s, 3H, N-CH3), 2.60 (s, 3H, pyrazole CH3); IR (KBr): ν 3241, 1648, 1499, 1279, 1096 cm−1; HR-ESI-MS m/z: 284.0347 [M+H]+ (calcd. for C12H12Cl2N3O, 284.0352).
1,3-Dimethyl-N-3',5'-dichlorobenzyl-1H-pyrazole-4-carboxamide (7ad): Gray crystal, yield of 66.9%, m.p. 181.6–182.2 °C. 1H-NMR (CDCl3, 500 MHz) δ: 7.77 (s, 1H, pyrazole H), 7.54 (d, J = 1.5 Hz, 2H, Ar-H), 7.11 (s, 1H, Ar-H), 3.88 (s, 3H, N-CH3), 2.53 (s, 3H, pyrazole CH3); IR (KBr): ν 3265, 3211, 1698, 1614, 1503, 1403, 1142, 1063 cm−1; HR-ESI-MS m/z: 284.0357 [M+H]+ (calcd. for C12H12Cl2N3O, 284.0352).
1,3-Dimethyl-N-(1,3,4-thiadiazole-2-yl)-1H-pyrazole-4-carboxamide (7ae): White lamellar crystal, yield of 57.2%, m.p. 278.4–278.9 °C. 1H-NMR (DMSO-d6, 500 MHz) δ: 12.52 (s, 1H, NH), 9.15 (s, 1H, pyrazole H), 8.55 (s, 1H, thiadiazole H), 3.82 (s, 3H, N-CH3), 2.50 (s, 3H, pyrazole CH3); IR (KBr): ν 3381, 3124, 2929, 1680, 1548, 1415, 1311 cm−1; HR-ESI-MS m/z: 224.0597 [M+H]+ (calcd. for C8H10N5OS, 224.0601).
1,3-Dimethyl-N-(5-ethyl-1,3,4-thiadiazole-2-yl)-1H-pyrazole-4-carboxamide (7af): White powder, yield of 68.3%, m.p. 266.2–266.5 °C. 1H-NMR (CDCl3, 400 MHz) δ: 12.58 (s, 1H, NH), 9.13 (s, 1H, pyrazole H), 3.94 (s, 3H, N-CH3), 3.07 (q, J = 1.0 Hz, 2H, CH2), 2.56 (s, 3H, pyrazole CH3), 1.45 (t, J = 1.0 Hz, 3H, CH3); IR (KBr): ν 3129, 2971, 2934, 1673, 1544, 1420, 1316, 1241, 1179 cm−1; HR-ESI-MS m/z: 252.0912 [M+H]+ (calcd. for C10H14N5OS, 252.0914).
1,3-Dimethyl-N-(5-methyl-1,3,4-thiadiazole-2-yl)-1H-pyrazole-4-carboxamide (7ag): White powder, yield of 61.4%, m.p. >300 °C. 1H-NMR (CDCl3, 400 MHz) δ: 9.12 (s, 1H, pyrazole H), 3.96 (s, 3H, N-CH3), 2.72 (s, 3H, thiadiazole CH3), 2.56 (s, 3H, pyrazole CH3); IR (KBr): ν 3149, 3012, 2921, 1677, 1544, 1494, 1416, 1320, 1250, 1188 cm−1; HR-ESI-MS m/z: 238.0755 [M+H]+ (calcd. for C9H12N5OS, 238.0757).
1,3-Dimethyl-N-(5-trifluoromethyl-1,3,4-thiadiazole-2-yl)-1H-pyrazole-4-carboxamide (7ah): White lamellar crystal, yield of 44.3%, m.p. 272.1–272.8 °C. 1H-NMR (CDCl3, 500 MHz) δ: 12.61 (s, 1H, NH), 9.12 (s, 1H, pyrazole H), 3.98 (s, 3H, N-CH3), 2.58 (s, 3H, pyrazole CH3); IR (KBr): ν 1668, 1519, 1303, 1195, 1137, 1029 cm−1; HR-ESI-MS m/z: 292.0471 [M+H]+ (calcd. for C9H9F3N5OS, 292.0474).
5-Methylisoxazol-3-yl 1,3-dimethyl-1H-pyrazole-4-carboxylate (7ai): White powder, yield of 54.7%, m.p. 124.2–124.4 °C. 1H-NMR (CDCl3, 500 MHz) δ: 7.98 (s, 1H, pyrazole H), 6.23 (s,1H, isoxazole H), 3.88 (s, 3H, N-CH3), 2.49 (s, 3H, pyrazole CH3), 2.43 (s, 3H, isoxazole CH3); IR (KBr): ν 3120, 1743, 1622, 1548, 1232, 1050 cm−1; HR-ESI-MS m/z: 222.0871 [M+H]+ (calcd. for C10H12N3O3, 222.0873).
1-Methyl-N-(2-hydroxyl)benzyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (7ba): Light yellow crystal, yield of 41.8%, m.p. 192.8–193.2 °C. 1H-NMR (DMSO-d6, 500 MHz) δ: 9.24 (s, 1H, -OH), 8.54 (s, 1H, pyrazole H), 7.65 (d, J = 7.5 Hz, 1H, Ar-H), 6.98 (d, J = 7.5 Hz, 1H, Ar-H), 6.88 (d, J = 7.5 Hz, 1H, Ar-H), 6.79 (d, J = 8.0 Hz, 1H, Ar-H), 3.94 (s, 3H, N-CH3); IR (KBr): ν 3485, 3116, 1656, 1598, 1494, 1441, 1329, 1250, 1175, 1146 cm−1; HR-ESI-MS m/z: 286.0804 [M+H]+ (calcd. for C12H11F3N3O2, 286.0798).
1-Methyl-N-(4-hydroxyl)benzyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (7bb): light brown powder, yield of 67.9%, m.p. 206.4–206.6 °C. 1H-NMR (DMSO-d6, 500 MHz) δ: 9.88 (s, 1H, NH), 9.25 (s, 1H, -OH), 8.44 (s, 1H, pyrazole H), 7.38–7.43 (m, 2H, Ar-H), 6.69–6.72 (m, 2H, Ar-H), 3.98 (s, 3H, N-CH3); IR (KBr): ν 1627, 1553, 1436, 1329, 1142, 839, 781, 711, 619, 516 cm−1; HR-ESI-MS m/z: 286.0800 [M+H]+ (calcd. for C12H11F3N3O2, 286.0798).
1-Methyl-N-2',4'-dichlorobenzyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (7bc): White crystal, yield of 49.0%, m.p. 147.4–147.8 °C. 1H-NMR (CDCl3, 400 MHz) δ: 8.43 (d, J = 7.2 Hz, 1H, Ar-H), 8.04 (s, 1H, pyrazole H), 7.43 (d, J = 2.0 Hz, 1H, Ar-H), 7.26–7.30 (m, overlapped, Ar-H), 4.02 (s, 3H, N-CH3); IR (KBr): ν 2958, 1785, 1640, 1565, 1424, 1333, 1291, 1146, 1047, 847, 781, 706 cm−1; HR-ESI-MS m/z: 338.0066 [M+H]+ (calcd. for C12H9Cl2F3N3O, 338.0069).
1-Methyl-N-3',5'-dichlorobenzyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (7bd): White powder, yield of 53.2%, m.p. 149.1–150.3 °C. 1H-NMR (CDCl3, 500 MHz) δ: 8.42 (d, J = 9.0 Hz, Ar-H), 8.03 (s, 1H, pyrazole H), 7.42 (d, J = 2.0 Hz, 1H, Ar-H), 7.26–7.30 (m, overlapped, Ar-H), 4.01 (s, 3H, N-CH3); IR (KBr): ν 3299, 3162, 3100, 1669, 1582, 1523, 1494, 1461, 1387, 1304 cm−1; HR-ESI-MS m/z: 338.0075 [M+H]+ (calcd. for C12H9Cl2F3N3O, 338.0069).
1-Methyl-N-(1,3,4-thiadiazole-2-yl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (7be): White floccus, yield of 49.6%, m.p. >300 °C. 1H-NMR (DMSO-d6, 500 MHz) δ: 12.99 (s, 1H, NH), 9.21 (s, 1H, thiadiazole H), 8.76 (s, 1H, pyrazole H), 3.99 (s, 3H, N-CH3); IR (KBr): ν 3170, 3116, 3054, 1689, 1557, 1436, 1316, 1175, 1134, 1059, 1005, 872 cm−1; HR-ESI-MS m/z: 278.0320 [M+H]+ (calcd. for C8H7F3N5OS, 278.0318).
1-Methyl-N-(5-ethyl-1,3,4-thiadiazole-2-yl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (7bf): White powder, yield of 56.9%, m.p. 288.6–288.8 °C. 1H-NMR (DMSO-d6, 500 MHz) δ: 12.82 (s, 1H, NH), 8.72 (s, 1H, pyrazole H), 3.96 (s, 3H, N-CH3), 2.98 (q, J = 7.5 Hz, 2H, CH2), 1.29 (t, J = 7.5 Hz, 3H, CH3); IR (KBr): ν 3456, 3054, 2963, 1694, 1627, 1557, 1424, 1341, 1308, 1171, 1129 cm−1; HR-ESI-MS m/z: 306.0631 [M+H]+ (calcd. for C10H11F3N5OS, 306.0631).
1-Methyl-N-(5-trifluoromethyl-1,3,4-thiadiazole-2-yl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (7bg): White crystal, yield of 71.2%, m.p. 234.9–235.1 °C. 1H-NMR (DMSO-d6, 500 MHz) δ: 13.68 (s, 1H, NH), 8.81 (s, 1H, pyrazole H), 4.01 (s, 3H, N-CH3); IR (KBr): ν 3456, 3070, 2963, 1694, 1627, 1557, 1424, 1341, 1308, 1183, 885, 711 cm−1; HR-ESI-MS m/z: 346.0191 [M+H]+ (calcd. for C9H6F6N5OS, 346.0192).
1-Methyl-N-2'-fluorobenzyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (7bh): Brown crystal, yield of 74.3%, m.p. 148.4~148.9 °C. 1H-NMR (CDCl3, 500 MHz) δ: 8.38 (m, 1H, Ar-H), 8.03 (s, 1H, pyrazole H), 8.00–8.03 (m, 1H, Ar-H), 7.08–7.18 (m, 2H, Ar-H), 4.00 (s, 3H, N-CH3); IR (KBr): ν 3245, 1652, 1565, 1507, 1441, 1316, 1217, 1183 cm−1; HR-ESI-MS m/z: 288.0757 [M+H]+ (calcd. for C12H10F4N3O, 288.0755).
1-Methyl-N-3'-fluorobenzyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (7bi): Brown crystal, yield of 47.9%, m.p. 137.8–138.3 °C. 1H-NMR (CDCl3, 500 MHz) δ: 8.04 (s, 1H, pyrazole H), 7.76 (s, 1H, Ar-H), 7.58 (d, J = 10.5 Hz, 1H, Ar-H), 7.18 (d, J = 8.5 Hz, 1H, Ar-H), 6.87 (t, J = 8.5 Hz, 1H, Ar-H), 4.01 (s, 3H, N-CH3); IR (KBr): ν 3494, 3373, 3261, 1664, 1602, 1561, 1329, 1300, 1188 cm−1; HR-ESI-MS m/z: 288.0757 [M+H]+ (calcd. for C12H10F4N3O, 288.0755).
1-Methyl-N-3',4'-difluorobenzyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (7bj): Light brown crystal, yield of 63.2%, m.p. 155.7–155.8 °C. 1H-NMR (CDCl3, 400 MHz) δ: 8.04 (s, 1H, pyrazole H), 7.78 (s, 1H, Ar-H), 7.69 (d, J = 7.5 Hz, 1H, Ar-H), 7.15 (d, J = 7.0 Hz, 1H, Ar-H), 4.00 (s, 3H, N-CH3); IR (KBr): ν 3241, 1652, 1557, 1519, 1432, 1329, 1300, 1208, 1146, 1051, 827, 752 cm−1; HR-ESI-MS m/z: 306.0663 [M+H]+ (calcd. for C12H9F5N3O, 306.0660).
5-Methylisoxazol-3-yl 1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate (7bk): White powder, yield of 58.9%, m.p. 130.7–131.1 °C. 1H-NMR (CDCl3, 400 MHz) δ: 8.19 (s, 1H, pyrazole H), 6.28 (s, 1H, isoxazole H), 4.03 (s, 3H, N-CH3), 2.45 (s, 3H, isoxazole CH3); IR (KBr): ν 3290, 1660, 1561, 1523, 1436, 1300, 1134, 1059, 856, 823, 711, 648 cm−1; HR-ESI-MS m/z: 276.0595 [M+H]+ (calcd. for C10H9F3N3O3, 276.0591).

3.6. Antifungal Bioassays

The fungicidal activity of the target Compounds 7aabk were tested in vitro against the phytopathogenic fungi A. porri, M. coronaria, C. petroselini and R. solani using the mycelium growth rate method [26,27]. The commercially available agricultural fungicide, carbendazol, was used as the positive control, whereas acetone served as the negative control. The compounds were dissolved in acetone to prepare a 100-μg/mL stock solution for the following antifungal test.
After the mycelia were incubated at 25 °C over a certain period, the diameter of each strain was measured. The percentage inhibition was calculated as follows:
I = (BA)/B × 100%
where I is the percentage of inhibition, A is the average mycelia diameter (mm) with the compounds in Petri dishes and B is the average mycelia diameter with the compounds in the blank Petri dishes.
The percentage inhibition of the compounds was determined at a dosage of 100 μg/mL. The compounds that displayed high activity (I > 50% at 100 μg/mL) were evaluated further at concentrations of 100, 50, 25, 12.5, 6.25 and 0 μg/mL. Three replicates were applied in each treatment. The EC50 (μg/mL) values were estimated statistically by Probit analysis using SPSS (version 11.5) on a personal computer.

4. Conclusions

In conclusion, a series of novel pyrazole carboxamides and isoxazolol pyrazole carboxylates was synthesized and characterized based on the spectral data of 1H-NMR, IR and MS in this study. The antifungal activity of the compounds was evaluated in vitro against the phytopathogenic fungi A. porri, M. coronaria, C. petroselini and R. solani. Among these compounds, the pyrazole carboxamides 7af, 7bc, 7bg, 7bh and 7bi exhibited moderate antifungal activity. The isoxazolol pyrazole carboxylate 7ai displayed strong antifungal activity against R. solani, with an EC50 value of 0.37 μg/mL. This value was better than that of the commercial fungicide, carbendazol. SAR analysis results suggested that the antifungal activity of the synthesized isoxazolol pyrazole carboxylate was significantly weakened when the methyl at the C-3 of the pyrazole ring was substituted with trifluoromethyl. Thus, these novel antifungal molecules can be considered promising lead compounds with which to explore biological activity in future research.

Supplementary Materials

Supplementary materials can be accessed at: https://www.mdpi.com/1420-3049/20/03/4383/s1.

Acknowledgments

This work was supported by High Level Talents Fund of Qingdao Agricultural University (No. 6631110) and Wheat Innovation Team of Modern Agricultural Industry Technology System of Shandong Province.

Author Contributions

J.S. designed the research. J.S. and Y.Z. performed the research and analyzed the data. Y.Z. wrote the paper. All authors read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sumangala, V.; Poojary, B.; Chidananda, N.; Fernandes, J.; Kumari, N.S. Synthesis and antimicrobial activity of 1,2,3-triazoles containing Quinoline moiety. Arch. Pharm. Res. 2010, 33, 1911–1918. [Google Scholar] [CrossRef] [PubMed]
  2. Mert, S.; Kasımoǧulları, R.; İça, T.; Çolak, F.; Altun, A.; Ok, S. Synthesis, structure activity relationships, and in vitro antibacterial and antifungal activity evaluations of novel pyrazole arboxylic and dicarboxylic acid derivatives. Eur. J. Med. Chem. 2014, 78, 86–96. [Google Scholar] [CrossRef]
  3. Gawad, N.M.A.; Georgey, H.H.; Ibrahim, N.A.; Amin, N.H.; Abdelsalam, R.M. Synthesis of novel pyrazole and dihydropyrazoles derivatives as potential anti-inflammatory and analgesic agents. Arch. Pharm. Res. 2012, 35, 807–821. [Google Scholar] [CrossRef] [PubMed]
  4. Ouyang, G.P.; Cai, X.J.; Chen, Z.; Song, B.A.; Bhadury, P.S.; Yang, S.; Jin, L.H.; Xue, W.; Hu, D.Y.; Zeng, S. Synthesis and antiviral activities of pyrazole derivatives containing an oxime moiety. J. Agric. Food Chem. 2008, 56, 10160–10167. [Google Scholar] [CrossRef] [PubMed]
  5. Rangaswamy, J.; Kumar, H.V.; Harini, S.T.; Naik, N. Synthesis of benzofuran based 1,3,5-substituted pyrazole derivatives: As a new class of potent antioxidants and antimicrobials-A novel accost to amend biocompatibility. Bioorg. Med. Chem. Lett. 2012, 22, 4773–4777. [Google Scholar] [CrossRef] [PubMed]
  6. Hassan, G.S.; Kadry, H.H.; Abou-Seri, S.M.; Ali, M.M.; Mahmoud, A.E.E. Synthesis and in vitro cytotoxic activity of novel pyrazolo[3,4-d]pyrimidines and related pyrazole hydrazones toward breast adenocarcinoma MCF-7 cell line. Bioorg. Med. Chem. 2011, 19, 6808–6817. [Google Scholar] [CrossRef] [PubMed]
  7. Turan-Zitouni, G.T.; Chevallet, P.; Kiliç, F.S.; Erol, K. Synthesis of some thiazolyl-pyrazoline derivatives and preliminary investigation of their hypotensive activity. Eur. J. Med. Chem. 2000, 35, 635–641. [Google Scholar] [CrossRef] [PubMed]
  8. Baraldi, P.G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Moro, S.; Klotz, K.; Leung, E.; Varani, K.; Gessi, S.; Merighi, S.; et al. Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A3 adenosine receptor antagonists: Influence of the Chain at the N8 pyrazole nitrogen. J. Med. Chem. 2000, 43, 4768–4780. [Google Scholar] [CrossRef] [PubMed]
  9. Lupsor, S.; Aonofriesei, F.; Iovu, M. Antibacterial activity of aminals and hemiaminals of pyrazole and imidazole. Med. Chem. Res. 2012, 21, 3035–3042. [Google Scholar] [CrossRef]
  10. Palaska, E.; Aytemir, M.; Uzbay, I.T.; Erol, D. Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines. Eur. J. Med. Chem. 2001, 36, 539–543. [Google Scholar] [CrossRef] [PubMed]
  11. Sauter, H.; Steglich, W.; Anke, T. Strobilurins: Evolution of a new class of active substances. Angew. Chem. Int. Ed. 1999, 38, 1328–1349. [Google Scholar] [CrossRef]
  12. Shiga, Y.; Okada, I.; Ikeda, Y.; Takizawa, E.; Fukuchi, T. Insecticidal activity of N-(4-aryloxybenzyl)pyrazole-5-carboxamides. J. Pestic. Sci. 2003, 28, 313–314. [Google Scholar] [CrossRef]
  13. Ohno, R.; Watanabe, A.; Matsukawa, T.; Ueda, T.; Sakurai, H.; Hori, M.; Hirai, K. Synthesis and herbicidal activity of new pyrazole-4-carboxamide derivatives. J. Pestic. Sci. 2004, 29, 15–26. [Google Scholar] [CrossRef]
  14. Zhou, Y.Y.; Li, Y.X.; Li, Y.M.; Yang, X.P.; Mao, M.Z.; Li, Z.M. Design, synthesis and structure-activity of N-glycosyl-1-pyridyl-1H-pyrazole-5-carboxamide as Inhibitors of Calcium channels. Chem. Res. Chin. Univ. 2013, 29, 249–255. [Google Scholar] [CrossRef]
  15. Lv, H.S.; Wang, L.Y.; Ding, X.L.; Wang, X.H.; Zhao, B.X.; Zuo, H. Synthesis and antifungal activity of novel (1-arylmethyl-3-aryl-1Hpyrazol-5-yl)(4-arylpiperazin-1-yl)methanone derivatives. J. Chem. Res. 2013, 37, 473–475. [Google Scholar] [CrossRef]
  16. Okada, I.; Okui, S.; Sekine, M.; Takahashi, Y.; Fukuchi, T. Synthesis and acaricidal activity of bicyclic pyrazole-3-carboxamide derivatives. J. Pestic. Sci. 1992, 17, 69–73. [Google Scholar] [CrossRef]
  17. Lamberth, C.; Dinges, J. Pyrazol carboxamide fungicides inhibiting succinate dehydrogenase. In Bioactivity Heterocylic Compound Classes: Agrochemicals, 1st ed.; Wiley-VCH Verlag GmBH & Co. KGaA: Weinheim, Germany, 2012; pp. 175–194. [Google Scholar]
  18. Liu, F.; Wang, M.Y.; Teng, X.H.; Zhang, P.Z.; Jiang, L. Synthesis and biological evaluation of novel 2-(substituted isoxazol-4-yl)-5-arylamino-1,3,4-oxadiazoles. Res. Chem. Intermed. 2014, 40, 1575–1581. [Google Scholar] [CrossRef]
  19. Cernuchova, P.; Vo-Thanh, G.; Milata, V.; Loupy, A. Solvent-free synthesis of quinolone derivatives. Heterocycles 2004, 64, 177–191. [Google Scholar] [CrossRef]
  20. Nishiwaki, N.; Matsushima, K.; Chatani, M.; Tamura, M.; Ariga, M. New reactivity of nitropyrimidinone: Ring transformation and N-C transfer reactions. Synlett 2004, 15, 703–707. [Google Scholar] [CrossRef]
  21. Toshio, K.; Kenji, O.; Takao, O. Preparation of 1,3-Dialkylpyrazole-4-Carboxylic Acid Esters. Jpn. Kokai Tokkyo Koho JP 2,000,044,541, 15 February 2000. [Google Scholar]
  22. Kenji, H.; Bunta, W.; Osamu, K.; Seiichi, K.; Takashi, K.; Junko, S. Preparation of N-(1-Phenyl-1H-pyrazol-4-yl)-1H-pyrazole-4-carboxamide Derivatives as Agrochemical Fungicides. Jpn. Kokai Tokkyo Koho JP 2,010,202,649, 16 September 2010. [Google Scholar]
  23. Palanki, M.S.S.; Erdman, P.E.; Gayo, F.; Leah, M.; Shevlin, G.I.; Sullivan, R.W.; Suto, M.J.; Goldman, M.E.; Ransone, L.J.; Bennett, B.L.; et al. Inhibitors of NF-κB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethyl pyrimidine-5-[N-(3',5'-bis(trifluoromethyl)-phenyl) carboxamide]. J. Med. Chem. 2000, 43, 3995–4004. [Google Scholar] [CrossRef]
  24. Sun, J.L. 3-Trifluoromethyl-4-formyl Pyrazol Compounds. CN Patent 103,554,026A, 5 February 2014. [Google Scholar]
  25. Sun, J.L. 3-Methyl-4-formyl Pyrazol Compounds. CN Patent 103,524,417A, 22 January 2014. [Google Scholar]
  26. Xu, G.F.; Song, B.A.; Pinaki, S.B.; Yang, S.; Zhang, P.W.; Jin, L.H.; Xue, W.; Hu, D.Y.; Lu, P. Synthesis and antifungal activity of novel s-substituted-6-fluoro-4-alkyl(aryl) thioquinazoline derivatives. Bioorg. Med. Chem. 2007, 15, 3768–3774. [Google Scholar] [CrossRef] [PubMed]
  27. Tarun, K.C.; Prem, D.J. Antifungal activity of 4-methyl-6-alkyl-2H-pyran-2-ones. J. Agric. Food Chem. 2006, 54, 2129–2133. [Google Scholar] [CrossRef] [PubMed]
  • Sample Availability: Samples of the compounds 7aabk are available from the authors.

Share and Cite

MDPI and ACS Style

Sun, J.; Zhou, Y. Synthesis and Antifungal Activity of the Derivatives of Novel Pyrazole Carboxamide and Isoxazolol Pyrazole Carboxylate. Molecules 2015, 20, 4383-4394. https://doi.org/10.3390/molecules20034383

AMA Style

Sun J, Zhou Y. Synthesis and Antifungal Activity of the Derivatives of Novel Pyrazole Carboxamide and Isoxazolol Pyrazole Carboxylate. Molecules. 2015; 20(3):4383-4394. https://doi.org/10.3390/molecules20034383

Chicago/Turabian Style

Sun, Jialong, and Yuanming Zhou. 2015. "Synthesis and Antifungal Activity of the Derivatives of Novel Pyrazole Carboxamide and Isoxazolol Pyrazole Carboxylate" Molecules 20, no. 3: 4383-4394. https://doi.org/10.3390/molecules20034383

Article Metrics

Back to TopTop